111 related articles for article (PubMed ID: 21905526)
61. Early adoption of cyclosporine and recombinant human erythropoietin: clinical, economic, and policy issues with emergence of high-cost drugs.
Powe NR; Eggers PW; Johnson CB
Am J Kidney Dis; 1994 Jul; 24(1):33-41. PubMed ID: 8023822
[TBL] [Abstract][Full Text] [Related]
62. Medicaid reform causes major 340B program changes in Illinois.
Traynor K
Am J Health Syst Pharm; 2012 Sep; 69(17):1451-2. PubMed ID: 22899734
[No Abstract] [Full Text] [Related]
63. The Inevitable Math behind Entitlement Reform.
Chernew ME; Frakt AB
N Engl J Med; 2018 Jul; 379(3):211-213. PubMed ID: 30021098
[No Abstract] [Full Text] [Related]
64. Move beyond denial. Providers must accept that cuts are coming in government healthcare programs.
Berman H; McPherson B
Mod Healthc; 2011 Aug; 41(33):18. PubMed ID: 21882385
[No Abstract] [Full Text] [Related]
65. Health care reform and older adults.
Gorin SH
Health Soc Work; 2010 Feb; 35(1):3-6. PubMed ID: 20218448
[No Abstract] [Full Text] [Related]
66. CMS panel examines states' challenges with Medicare reform.
Young D
Am J Health Syst Pharm; 2004 Aug; 61(16):1651-3. PubMed ID: 15540475
[No Abstract] [Full Text] [Related]
67. Debt crisis: opportunity for nursing action.
Miller ET
Rehabil Nurs; 2011; 36(6):224, 232. PubMed ID: 22073500
[No Abstract] [Full Text] [Related]
68. The 70:30 health care system.
Van Way CW
JPEN J Parenter Enteral Nutr; 2007; 31(1):72-4. PubMed ID: 17202445
[No Abstract] [Full Text] [Related]
69. 'Locked storage' addressed in CMS's new interpretive guidelines.
Young D
Am J Health Syst Pharm; 2004 Aug; 61(16):1648, 1651. PubMed ID: 15540474
[No Abstract] [Full Text] [Related]
70. Health care payment policies: lessons from erythropoietin.
Abraham PA
Am J Kidney Dis; 1993 Oct; 22(4):596-7. PubMed ID: 8213802
[No Abstract] [Full Text] [Related]
71. A Policy That Encourages Wastage of Expensive Medications-The JW Modifier.
Goldstein DA; Hirsch A
JAMA Oncol; 2018 Feb; 4(2):155-156. PubMed ID: 29222558
[No Abstract] [Full Text] [Related]
72. Medicare rate for Aranesp delayed.
Nephrol News Issues; 2002 Feb; 16(3):10. PubMed ID: 11859740
[No Abstract] [Full Text] [Related]
73. Oncology Care in 2021: the FDA, Medicare, and healthcare reform.
Gottlieb S; Gustafson TA; Johnson DH
Oncology (Williston Park); 2011 May; 25(6):445, 449. PubMed ID: 21717897
[No Abstract] [Full Text] [Related]
74. Cyclosporine and the financial plight of organ transplant recipients.
Helgeson MD
Nephrol News Issues; 1992 Aug; 6(8):12, 16. PubMed ID: 1407062
[No Abstract] [Full Text] [Related]
75. Drug rebates revisited.
Lewis NJ; McGhan WF; Wertheimer AI
Health Aff (Millwood); 1992; 11(1):286-7. PubMed ID: 1577387
[No Abstract] [Full Text] [Related]
76. Timeline and potential impact of CMS's drug competitive acquisition program (CAP).
Rubinstein E
J Manag Care Pharm; 2006 Apr; 12(3):263-4. PubMed ID: 16623612
[No Abstract] [Full Text] [Related]
77. Update to Epogen information in article on future drug expenditures.
Evens PE
Am J Health Syst Pharm; 1995 Jun; 52(12):1348-9. PubMed ID: 7656127
[No Abstract] [Full Text] [Related]
78. Can the cost of erythropoietin for cardiac surgery patients be justified?
Strauss RG
Transfusion; 1994 Sep; 34(9):835. PubMed ID: 8091475
[No Abstract] [Full Text] [Related]
79. Medicare Coverage Strategies: Impact of the MMA and PBMs.
Antos J
Am Health Drug Benefits; 2008 Feb; 1(1):15-20. PubMed ID: 25126207
[TBL] [Abstract][Full Text] [Related]
80. Message Received.
Sorrel AL
Tex Med; 2016 Jan; 112(1):37-42. PubMed ID: 26821127
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
